Clinical Research Billing Basics & How to Develop a Coverage Analysis
|
|
- Mitchell Barnaby Barton
- 8 years ago
- Views:
Transcription
1 Clinical Research Billing Basics & How to Develop a Coverage Analysis Julie Colasacco & Michael C. Roach Presented at Virginia Commonwealth University August 29, N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com
2 Goals Raise Awareness Teach knowledge transfer 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 2
3 Important Terms & Acronyms Clinical Research Billing CRB Medicare Clinical Trial Policy CTP Qualifying Clinical Trial QCT Centers for Medicare & Medicaid Services CMS 3
4 Overview 1. Regulatory risks of clinical research billing non-compliance 2. The importance of a Coverage Analysis (CA) for compliance 3. An overview of Medicare rules for billing during clinical research studies 4. The basics of billing for research team members 5. How the budget structure influences what can be billed to insurance 6. How the language of the Informed Consent Form influences what can be billed to insurance 7. What does Medicare mean by a qualifying clinical trial? 8. What does Medicare mean by routine costs? 9. The importance of the research coordinator in ensuring clinical research billing is compliant 10. Tips on protocol design for investigator-initiated studies to improve budgeting and billing 11. The role of the study calendar in clinical research billing 12. Improving communications during the research study 4
5 Overview 13. Pause for Questions 14. Introduction to the Coverage Analysis: Purposes 15. Review of forms needed 16. Development of a Coverage Analysis Step 1: Draft a grid Step 2: Review ICF Step 3: Review CTA/Budget Step 4: QCT Analysis Step 5: Which are routine costs? Step 6: How to document reasoning Step 7: Coding the CA 5
6 1. Regulatory risks of clinical research billing non-compliance 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 6
7 Risks Associated With Non-Compliance CRB risks can be grouped: 1. Billing for services that are already paid by the sponsor (double billing) 2. Billing for services promised free in the informed consent 3. Billing for services that are for research-purposes only 4. Billing for services that are part of a non-qualifying clinical trial 5. Billing Medicare Advantage Plan when claim should be directed to Medicare Administrative Contractor ( MAC ) 7
8 Challenges Cause of most research billing non-compliance: Breakdown in coordination Important information to coordinate What research studies are being conducted at the facility? Which patients are enrolled in a research study? Which services should be charged to payors and which charged to study account? Sponsor, grant, internal account Informed consent language Clinical trial agreement language Protocol Language 8
9 Coordination Who impacts research billing? Principal Investigator Clinical Research Coordinator vital communication coordinator IRB process Budget negotiators Clinical Trial Agreement negotiators Grant administration Information Technology Health Information Management Registration/Scheduling Medical center billing and coding Physician professional fee billing and coding Study fund managers Managed care contract negotiators.and others! 9
10 Current Research Regulatory Environment Cases of improper clinical trials billing Tenet Healthcare (Norris Cancer Ctr) Northwestern University Rush University Million Dollars Mayo Clinic Yale $0.0 $1.0 $2.0 $3.0 $4.0 $5.0 $6.0 $7.0 $
11 2. The importance of a Coverage Analysis (CA) for compliance 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 11
12 What is a Coverage Analysis? Systematic review of research related documents to determine the Medicare billing status of both the study itself and the items and services provided to the research subjects that are required by the study A tool to coordinate information for purposes of: Budgeting Billing Auditing 12
13 What a Coverage Analysis is not Guarantee of coverage in all cases Substitute for the pre-authorization process Based on individual investigators decisions or billing practices Substitute for the practice of medicine or physician judgment Treatment plan Black and white or perfect translation 13
14 Hypothetical CA: a way to coordinate information Physical Exam Code Infusion 1 Infusion 2 EKG RC RC RC Drug 123 J0123 SB SB Infusion RC RC Urinalysis NB NB Ultrasound ICF 2 weeks 12 weeks 24 weeks Comment RC RC RC RC Patient Diary N/A NB NB NB NB RC=Routine Care SB=Sponsor Billed ICF=Free in Informed Consent NB=Not billable to Medicare Aegis Aegis Compliance Compliance & Ethics & Ethics Center, Center, LLP LLP 14
15 3. An overview of Medicare rules for billing during clinical research studies 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 15
16 True or False? Medicare pays for standard of care during research studies. False: Medicare pays for routine costs during qualifying clinical trials 16
17 True or False? My friend in California says this service is covered when she provides it, so it s covered for us, too. Maybe: Medicare Administrative Contractors ( MACs ) can issue local coverage determinations ( LCDs ) that limit coverage in their area. If your friend has a different MAC, you may not be able to bill a service that she can. Possible for your friend to have a different MAC even if she works at a facility down the street from you 17
18 True or False? We have billed for this service hundreds of times and the claim is always paid by Medicare, so it must be covered. False: You cannot assume that just because Medicare has been paying for a service that it is a covered service 18
19 True or False? You are making clinical decisions when you decide something is not billable to Medicare. False. Decisions about whether a service is covered is not a clinical decision. It is a decision based on an analysis of the billing rules and coverage determinations made by CMS and Medical Directors at MACs. 19
20 Medicare s CRB Framework Medicare requires a five-part process for clinical research services coverage: 1. Does the study qualify for coverage? 2. What items and services are routine costs? 3. Do Medicare rules allow coverage of specific routine costs within a research study? 4. What is paid for by the sponsor? 5. What is promised free in the informed consent? 20
21 4. The basics of billing for research team members N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com
22 Billing Basics Before getting into the details of CRB, it is important to step back and understand: The billing system in the U.S. The structure of the Medicare Program Medicare is a driver of reimbursement across many payors, particularly for CRB Understanding some of the basics helps with budgeting, putting the CRB rules in context, and improves claims management 22
23 Structure of Medicare reimbursement for an outpatient service Service Technical component Professional component Medicare pays a technical component and professional component for all Part B services. Who receives which component depends upon the place of service.
24 Service provided in a physician office setting Service Technical component Professional component Medicare pays physician both components in one payment
25 Service provided in a hospital outpatient setting Service Technical component Professional component Medicare pays hospital Medicare pays physician
26 The Legal Structure of Medicare To understand Medicare research billing rules, it is important to step back and understand the legal structure of Medicare Statutory basis for Medicare coverage follows this principle: Medicare covers items and services that are reasonable and necessary to diagnose or treat illness or injury Known as the Reasonable & Necessary Rule 26
27 The Hierarchy of Medicare Rules The Statute National CMS National Coverage Determinations ( NCDs ) Manuals (e.g., Medicare Benefit Policy Manual, Medicare Claims Processing Manual) Local - MACs Local Coverage Determinations ( LCDs ) Medical Director articles Medical Director rulings Reasonable & Necessary Rule Document medical necessity when no coverage rule 27
28 Medicare Contractors Have Wide Discretion Example: CyberKnife No national uniform policy; regional decision Geography Has Role in Medicare Cancer Coverage, NYT December 16, 2008 [G]eography may play as big a role as medicine in determining which men diagnosed with prostate cancer are eligible for CyberKnife. As it turns out, Medicare pays for the treatments in 33 states but not in 17 others. Our guidance to them is that if there s no evidence it works, they shouldn t pay for it, said Dr. Steve Phurrough, Medicare s coverage director in Washington. The CyberKnife is a good example of a technology where you can review the evidence and come to different conclusions. 28
29 Implications of hospital vs. physician billing in CRB process The answer in the CA will be the same for hospital billing and physician billing but how the charges are presented on the claim forms will look very differently Hospital billing and physician billing should usually match during a research study with respect to when services are charged to the study account and when the item or service is billed normally Payment for hospital services versus physician services varies immensely Budgeting must take into account both the hospital charge and the physician charge (if the service is hospital-based) 29
30 5. How the budget structure influences what can be billed to insurance N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com
31 Medicare s CRB Framework Medicare requires a five-part process for clinical research services coverage: 1. Does the study qualify for coverage? 2. What items and services are routine costs? 3. Do Medicare rules allow coverage of specific routine costs within a research study? 4. What is paid for by the sponsor? 5. What is promised free in the informed consent? 31
32 First things first: What is a clinical trial agreement? A clinical trial agreement (CTA) sets out the obligations of parties involved in a research study The CTA sets out: what services are to be performed who does what who owns what how much money will be paid for which services extra regulatory obligations the parties will take on the rules of the road between the parties 32
33 Why is the CTA important for the research billing process? Whatever is paid for by the sponsor in the CTA cannot be billed to the subject or the subject s insurer If the CTA is not clear on what is being paid for by the sponsor, the document may be misinterpreted both by the sponsor and by regulators in the event of an audit The information in the CTA on what the sponsor is paying for must be communicated to the billing process Institutions may suffer unintended consequences based on what is written in the CTA 33
34 Non-industry contracts The concepts in this presentation apply equally to contracts for funding support with non-industry sponsors Most CRB compliance risks can occur without respect to whether the sponsor is industry, government, or a private foundation Negotiators of government contracts should coordinate with the individuals who negotiate the budget and be cognizant of their impact on the CRB process Offices within organizations that deal with government contracts should be brought into the CRB process training 34
35 What and where is the study budget? The study budget for industry-sponsored studies is typically an appendix or exhibit to the CTA and serves as the compensation detail The study budget and the main body of the contract are part of the same document they will be interpreted together 35
36 Operational issues that could impact the CRB process Many clinical trial agreements have been negotiated in parts One person negotiates the main body Another person negotiates the budget /compensation Protocol is incorporated but may not be reviewed carefully by either person, particularly if there is no formal MCA process in place Fundamental principle of Clinical Trial Agreements Singularity: A CTA is one contract with many parts Interpreted as a single legal document 36
37 Bringing a CRB perspective early to a CTA Best practice CRB processes analyze both the main body of the CTA and the study budget exhibit from a billing perspective Goal: Clarity in the final documents If sponsor is paying for all services, then the CTA and study budget should be clear and that should be reflected in a Medicare Coverage Analysis (MCA) or other communication tool to inform the CRB process If sponsor is only paying for some of the protocol services, then the study budget should be clear as to which services are being paid for so there is no confusion in developing the MCA Ambiguities in the CTA and study budget will usually be interpreted by insurers to their benefit (i.e., no billing) 37
38 Main body of the CTA: Case studies of language Examples of clauses (risky language): Payment for Study services are set out in Exhibit B. Such compensation constitutes payment for all of the Institution s costs for conducting Study services. Sponsor agrees to pay Institution in accordance with Exhibit B. Institution agrees not to bill any third-party payer for services required by the Study. Exhibit A sets out the payment schedule to Institution for Study services. Unscheduled imaging services shall be invoiced to sponsor at $350 per service. 38
39 Main body of the CTA: Case studies of language Examples of clauses (neutral language): During the term of the Study, Sponsor agrees to provide financial support for the Study in accordance with the budget set out in Exhibit A. Payment to Institution for items provided and services performed by Institution during the Study are set out in Exhibit A. Negotiations will not always be able to produce completely neutral language in the main body of the CTA; if the main body contains discussion of specifics of the financials, then be precise and ensure that the main body of the CTA and the study budget language do not contradict each other 39
40 Structure of Financial Provisions: Compensation Exhibit/ Study Budget There is no standard approach to the Compensation Exhibit each sponsor tends to have its own format Some structures utilized: Payments for research service at milestones Note: Is research service defined? Be clear which services are considered research services Spreadsheet with payments based on schedule of events Note: Best practice 40
41 Structure of Financial Provisions: Compensation Exhibit/ Study Budget Consider adopting a consistent approach for the compensation exhibits: the more detail on which services are being paid for, the better The MCA can serve as a tool for budgeting and lends itself to be used as the compensation exhibit Negotiating Suggestion: Watch out for footnotes! Avoid footnotes in the study budget, if possible 41
42 Operational issues that could impact the CRB process Many clinical trial agreements have been negotiated in parts One person negotiates the main body Another person negotiates the budget /compensation Protocol is incorporated but may not be reviewed carefully by either person, particularly if there is no formal MCA process in place Fundamental principle of Clinical Trial Agreements Singularity: A CTA is one contract with many parts Interpreted as a single legal document 4 2
43 Tips on protocol design for investigator-initiated studies to improve budgeting and billing 43
44 The design of the study impacts billing 3 Items to think about in protocols: 1. Loose use of the term research If the service is being used for research purposed and clinical care, then discuss the clinical care When a protocol only talks about the research aspects of a service, an auditor could ignore the clinical usefulness of the services 4 4
45 The design of the study impacts billing 3 Items to think about in protocols: 2. Stating a potential benefit If protocol or informed consent form states that the subject will receive no benefit from the study, then no services will be billable Describe in the protocol and the informed consent any potential benefit (though do not guarantee benefit) 4 5
46 The design of the study impacts billing 3 Items to think about in protocols: 3. What are the objectives in a Phase 1 study? Is it necessary in the study to state principal and secondary objectives of the study? Or can all objectives be stated without rank? Some Medicare Contractors and auditors have denied coverage to Phase 1 studies when measurement of therapeutic outcome is not a primary objective or a clearly articulated objective 4 6
47 6. How the language of the Informed Consent Form influences what can be billed to insurance N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com
48 Medicare s CRB Framework Medicare requires a five-part process for clinical research services coverage: 1. Does the study qualify for coverage? 2. What items and services are routine costs? 3. Do Medicare rules allow coverage of specific routine costs within a research study? 4. What is paid for by the sponsor? 5. What is promised free in the informed consent? 48
49 Role of the Informed Consent Form Interpreting the ICF ICF interpreted for MCA from the perspective of the subject Plain meaning of the words used in the informed consent Promises made to subject regarding what is free must be kept If two sentences in Costs section could reasonably be interpreted in a way that they contradict each other, then reword 49
50 Research Informed Consent: Context OHRP & FDA Rules: 45 CFR & 21 CFR 50.20: The information that is given to the subject or the representative shall be in language understandable to the subject or the representative. Goal: Language in 6 th to 8 th grade reading level Government reviews and audits of ICF: Interpreted from the perspective of the subject The ICF means what it says: assumes plain meaning of the terms 44
51 ICF & Added Costs Section Regulation: 45 CFR (b)(3) & 21 CFR 50.25(b)(3) require the ICF include, when appropriate, any additional costs to the subject that may result from participation in the research If the added costs section of the informed consent form states that an item or service will not be charged to the patient, then the provider cannot bill for that service Note: The regulation does not require that the ICF list the services that are or are not charged, rather it requires the ICF to list the additional costs the patient will incur as a result of participating in the study (many routine costs are not costs resulting from participation) 51
52 Problematic Added Costs Language You or your insurer will have no costs for participating in this research study. (Subject/insurer may not be billed for any protocol-required items or services, nor for complications/injuries or other costs associated with participation) Your routine medical care will be billed in the usual way. However, you will not be charged for any study visits or services. (Inconsistent terms within the same document) You will be responsible for the costs of any services you would have received if you did not enroll in this research study. However, you will not be billed for any lab services or imaging services. (Inconsistent terms within the same document) 52
53 Added Costs Section Contemplating the CRB Process Language which keeps the ICF neutral : You will be responsible for the costs of services required by the research study that are routine to treat your condition. You will not be responsible for the costs of services that are required only because you are enrolled in the research study. Language which specifically identifies services that will not be billed (if IRB desires specifics) You will be responsible for costs for care you would have received if you were not enrolled in this research. However, you will not be responsible for the costs of the CT scan conducted at the start of each drug cycle. 53
54 Medicare CRB Rules: The Regulatory Specifics 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 54
55 In a Nutshell Medicare covers routine costs in a qualifying clinical trial but note that all other Medicare rules still apply. 55
56 7. What does Medicare mean by a qualifying clinical trial? 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 56
57 Qualifying Status Research study must meet CMS qualifying clinical trial criteria for any items and services in the study to be confidently covered. Government and Drug Trials: CMS Clinical Trial Policy (NCD 310.1) Device Studies: Device study coverage rules from regulations and Medicare Benefit Policy Manual 42 CFR Part 405, Subpart B (42 CFR et seq.) Ch. 14 of the Medicare Benefit Policy Manual 51
58 Qualifying Clinical Trials ("QCTs") Part 1 Deemed Studies These studies are deemed to have 7 characteristics CMS wants to see in a study it will cover 1. Studies funded by NIH, CDC, AHRQ, CMS, DOD, and VA 2. Studies supported by centers or cooperative groups funded by NIH, CDC, AHRQ, CMS, DOD, and VA; 3. Studies being conducted under an IND application; or 4. IND exempt studies under 21 CFR 312.2(b)(1) 58
59 Qualifying Clinical Trials ( QCTs ) Part 2 Necessary Requirements 1. The study must investigate an item or service that Medicare pays for (falls in a benefit category) 2. The study must enroll patients with diagnosed disease 3. The study must have therapeutic intent 59
60 Benefit Category Test NCD lists 72 benefit categories Drug studies: Drugs and biologicals 60
61 Diseased Subjects Test Medicare only covers items and services that are reasonable and necessary to diagnose or treat illness or injury (with limited exceptions) Requirement comes from Medicare statutory principles CA documents the subjects diagnosis CTP: Trials of diagnostic interventions may enroll healthy patients in order to have a proper control group. 61
62 Therapeutic Intent Test For the time being, application of therapeutic intent criterion is deferred to local Medicare Contractors Principally an issue for Phase I drug studies Can be vast differences from one Medicare contractor to another 62
63 Therapeutic Intent There are two discussions of therapeutic intent in the CTP: The trial must not be designed exclusively to test toxicity or disease pathophysiology. It must have therapeutic intent. The principal purpose of the trial is to test whether the intervention potentially improves the participants' health outcomes. 63
64 Qualifying Clinical Trial Test - Recap It is really a four part test: Is the trial one of the deemed studies? Does the trial assess something in a Medicare Benefit Category? Does the trial enroll people with diagnosed disease? Does the trial have therapeutic intent? If no to any one of these, it is not a QCT 64
65 Qualifying /Approved Device Trials 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 65
66 Device Trials Always check with your Medicare Administrative Contractor is Palmetto for the Richmond Virginia area for their specific requirements 66
67 Category A Experimental Devices Generally not covered However, Medicare may cover routine costs, if the device is used for a life-threatening condition. Medicare contractor decides Device itself must be provided free 67
68 Category B Non-Experimental Devices These devices can be covered under Medicare. FDA approved IDE study protocols restrict investigational devices shipment to a limited number of clinical sites for testing on a specific number of patients. Medicare coverage is based on the device continuing to meet criteria that led to the FDA category designation 68
69 Clinical Trials Billing Medicare may cover procedures using devices with an IDE that have been categorized as non-experimental /investigational (Category B) Medicare only covers those procedures if: They involve a device the FDA has determined is nonexperimental/investigational (Category B), and The device is furnished in accordance with FDAapproved protocols governing clinical trials 69
70 8. What does Medicare mean by routine costs? 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 2013 Aegis Aegis Compliance & & Ethics Center, LLP LLP 70
71 Routine Costs from the Medicare CTP Items or services that are typically provided absent a clinical trial (e.g., conventional care); [Note: Not the same as standard of care ] Items or services required solely for the provision of the investigational item or service (e.g., administration of a noncovered chemotherapeutic agent), the clinically appropriate monitoring of the effects of the item or service, or the prevention of complications; and Items or services needed for reasonable and necessary care arising from the provision of an investigational item or service--in particular, for the diagnosis or treatment of complications. 71
72 Routine Costs Short Version 1. Detection, prevention, or monitoring of complications; 2. Administration of investigational item; or 3. Conventional care 72
73 Detecting, preventing, or monitoring complications Identify nexus between the item or service and a known potential side effect of the item or service What are the potential side effects of the drug? What are the potential complications of use of the device? 73
74 Detecting, preventing, or monitoring complications Places in which CAs identify potential side effects Protocol Informed Consent Product Label Drug compendium discussion AHFS-DI American Hospital Formulary Service Drug Information NCCN National Comprehensive Cancer Network Drugs & Biologics Compendium Thompson Micromedex DrugDex Clinical Pharmacology 74
75 Administration of Investigational Item What is required to administer the investigational item? Surgery? Infusion? Note: must be something that would be covered outside of study if similar therapy or procedure occurs. 75
76 Conventional Care CAs should identify objective practice guidelines 1. Professional association guidelines (e.g., National Comprehensive Cancer Network/NCCN) 2. Peer-reviewed literature 3. Significant textbooks 4. Disease-based associations 5. NIH recommendations 6. Guidelines.gov 76
77 Conventional Care: Example NCCN Practice Guidelines for Cancer of the Oropharynx: follow-up Physical exam Year 1: every 1-3 months Year 2: every 2-4 months Years 3-5: every 4-6 months > 5 Years: every 6-12 months 77
78 Additional Note: All Other Medicare Rules Apply Coverage is available if Medicare covers the routine cost outside of clinical trial MCA applies normal Medicare rules on top of any item or service identified as a routine cost 78
79 Other Medicare Rules Example: Rule against coverage of selfadministered drugs (Medicare Benefits Policy Manual, Ch. 15, Sec. 50.5) Exception examples: anti-emetics; oral anti-cancer drugs 79
80 Routine Costs vs. Standard of Care Just because the physician normally performs a service at a given frequency for similar patients not on trial does not mean the service qualifies as a routine cost E.g., PSA exams for prostate cancer patients Study calls for monthly PSA Physician typically does monthly PSA and argues they are therefore conventional care and consequently routine costs NCCN guidelines call for every 3 months No other objective evidence produced by physician to support medical necessity of monthly PSAs 80
81 Routine Costs vs. Standard of Care EKG performed 3 days after each infusion of cardio-toxic drug during trial Routine cost: detecting and monitoring known side effects Also performed at annual follow-up visits for life Is EKG at follow-up a routine cost? 81
82 9. The importance of the research coordinator in ensuring clinical research billing is compliant 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 82
83 83
84 10. Tips on protocol design for investigatorinitiated studies to improve budgeting and billing 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 84
85 The design of the study impacts billing 3 Items to think about in protocols: 1. Loose use of the term research If the service is being used for research purposed and clinical care, then discuss the clinical care When a protocol only talks about the research aspects of a service, an auditor could ignore the clinical usefulness of the services 85
86 The design of the study impacts billing 3 Items to think about in protocols: 2. Stating a potential benefit If protocol or informed consent form states that the subject will receive no benefit from the study, then no services will be billable Describe in the protocol and the informed consent any potential benefit (though do not guarantee benefit) 86
87 The design of the study impacts billing 3 Items to think about in protocols: 3. What are the objectives in a Phase 1 study? Is it necessary in the study to state principal and secondary objectives of the study? Or can all objectives be stated without rank? Some Medicare Contractors and auditors have denied coverage to Phase 1 studies when measurement of therapeutic outcome is not a primary objective or a clearly articulated objective 87
88 11. The role of the study calendar in clinical research billing 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 88
89 Study Calendars Study calendars help orient reviewers to where the subject is in the study The study calendar helps to sync the schedule of events with the CA Example: A charge for a CBC on 9/16/12 which CBC is it? 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 89
90 Hypothetical CA Code Baseline C1 W1 C1W2 C1W3 C1W4 C2W1 C2W2 Physical Exam S P P S P P CMP S P P S P P CBC S P P S P P Blood Draw S P P S P P DEXA scan Study Drug Admini stration S S S S S P P P P P
91 Collecting Protocol Event Dates John Smith ICF: 8/14/12 Physical Exam Code Baseline C1 W1 C1W2 C1W3 C1W4 C2W1 C2W2 8/16/12 9/2/12 9/9/12 9/16/12 10/6/12 10/13/12 CMP 8/16/12 9/1/12 9/9/12 9/16/12 10/6/12 10/13/12 CBC 8/16/12 9/1/12 9/9/12 9/16/12 10/6/12 10/13/12 Blood Draw DEXA scan Study Drug Admini stration 8/16/12 9/1/12 9/9/12 9/16/12 10/6/12 10/13/12 8/18/12 9/21/12 9/2/12 9/9/12 10/6/12 10/13/12 9/2/12 9/9/12 10/6/12 10/13/12
92 12. Improving communications during the research study 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 92
93 Reality This isn t going to happen overnight Try piloting ideas for CRB claims management Do not be afraid to re-think plan after results of piloting Personal Observation: We have yet to see a CRB process which after 1 year looks the same as its roll-out 93
94 The importance of databases Sharing information and communication is a critical feature of managing clinical research billing Databases and an information platform are the most common solutions 94
95 The importance of databases What information to collect? Study identification IRB status Subject enrollment Study calendars Coverage Analyses Study document housing 95
96 13. Pause for Questions 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 96
97 Workshop Discussion 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 97
98 14. Introduction to the Coverage Analysis: Purposes 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 98
99 Screening C1W1 C1W2 C1W3 C1W4 C2 W1 C2 W2 C2 W3 C2 W4 After Discontinuation Phys Exam X X X X X X X X X X ECG X X Echo cardiogram Chest CT or MRI , X X X X X X Abdominal CT or MRI , X X Pelvis CT or MRI , X X Bone Scan X X CBC w/diff X X X X X X X X X X Comprehensive Metabolic Panel X X X X X X X X X X Study Drug J9999 X X X X
100 Screening C1W1 C1W2 C1W3 C1W4 C2 W1 C2 W2 C2 W3 C2 W4 After Discontinuation Phys Exam P P P P P P P P P NB ECG P NB Echo cardiogram Chest CT or MRI , P S NB P P NB Abdominal CT or MRI , P NB Pelvis CT or MRI , P NB Bone Scan P NB CBC w/diff P P S S S P S S S NB Comprehensive Metabolic Panel P P S S S P S S S NB Study Drug J9999 S S P S
101 15. Review of forms needed 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 101
102 First Question Is the study a new study or a active study? 102
103 Basic Documents Needed Protocol CTA/Budget Funding Document Informed Consent Form IND Status drug study FDA IDE Letter device study 103
104 General Order of Steps for Developing an CA: Proposed Study : 1. Develop grid 2. Perform QCT analysis 3. Identify items and services hard-wired free into protocol 4. Determine items and services that are routine costs 5. Determine if routine costs are covered by Medicare 6. Check proposed contract to determine if offered budget covers items and services that are not billable 7. Negotiate contract/budget 8. Finalize added costs section of informed consent 9. Finalize grid once study approved 104
105 Sections 16 Development of a Coverage Analysis Step 1: Draft a grid Step 2: Review ICF Step 3: Review CTA/Budget Step 4: QCT Analysis Step 5: Which are routine costs? Step 6: Document reasoning Step 7: Coding the CA 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 105
106 General Order of Steps for Developing an CA: Active Study 1. Develop grid 2. What items and services are promised free in the informed consent? 3. What items and services are paid for by the sponsor? 4. Qualifying clinical trial (QCT) analysis 5. Determine items and services that are routine costs 6. Determine if routine costs are covered by Medicare 7. Apply Medicare rules to the routine costs 8. Finalize grid 106
107 Recall: Qualifying Clinical Trial Status
108 Document the QCT Analysis Process Question Yes No Comment Deemed study? Item or service falls within a benefit category? Enrolls subject with diagnosed disease? Study designed with therapeutic intent? Qualifying Clinical Trial? 108
109 Document the QCT Analysis Process Question Yes No Comment Deemed study? X IND # 55,512 Item or service falls within a benefit category? Enrolls subject with diagnosed disease? Study designed with therapeutic intent? Qualifying Clinical Trial? X X X X Drugs & Biologicals Crohn s Disease Include direct quote from protocol and reference page number To determine the efficacy of [study drug] in minimizing occurrences of abdominal pain over 24 week period. 109
110 Recall: Device Trial Qualifying Status Device Trial Coverage: Coverage deferred to Medicare Contractor approval or local rules Category A IDE: covered when studying a life-threatening condition Category B IDE: generally covered PMA: generally covered with approval and may not always need approval Note: Carotid Artery Stent PMAs must be approved by the Medicare Contractor Misc Situations: Labeled Use: generally covered because the study is likely not investigating the device, but collecting outcomes data HUD: requires approval by Medicare Contractor (not necessarily a trial) 110
111 Document Device Trial Qualifying Question Does the device have an IDE? Question Is the device approved by the FDA? Yes No Yes No Coverage Eligibility Summary If the device has an IDE what category is it? Category A Category B If the device is FDA approved is it being studies on-label or offlabel? On-Label Off-Label Comments Comments Question Yes No Supporting Explanation Is the study eligible for coverage? 111
112 Routine Cost Short version approach to routine costs used in MCAs: 1. Detection or prevention of complications 2. Conventional care 3. Administration of investigational item If study documents are not clear: will each subject enrolled in the study need the item or service for the patient s clinical management? 112
113 Which of the events are justified for billing under the coverage rules as routine costs? Physical Exam Code Infusion 1 Infusion 2 2 weeks 12 weeks 24 weeks EKG RC RC RC Drug 123 J9999 SB SB Infusion RC RC Urinalysis NB NB Ultrasound ICF RC RC RC RC Patient Diary N/A NB NB NB NB RC=Routine Care SB=Sponsor Billed ICF=Free in Informed Consent NB=Not billable to Medicare
114 Document Reasoning EKG: The EKG in this study is conventional care. Practice Guidelines for treatment of XYZ Condition recommend EKG at this frequency. [Cite Guidelines]. 114
115 Document Reasoning EKG: The EKG in this study is to detect complications. The study drug has known cardiotoxic effects. Protocol, p
116 Research Codes 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 116
117 Research Coding Principal matters: V70.7 diagnosis code Q0/Q1 modifiers Condition Code 30 (research setting) ClinicalTrials.gov number 117
118 Where to find the rules Medicare Claims Processing Manual Chapter 32, Section 69.6 Requirements for Billing Routine Costs in Clinical Trials Note: references to these research coding rules are scattered throughout Medicare rules and commentary, but the Claims Processing Manual provides the most concise resource and reference. 118
119 ClinicalTrials.gov number When a study is registered with clinicaltrials.gov (a website managed by the NIH), it is assigned an 8 digit number Providers may report the clinicaltrials.gov number on the claim form, but this is strictly voluntary today. New guidelines go into effect January 1, 2014 CMS conducts monthly aggregations of claims using the clinicaltrials.gov code 119
120 V70.7 Examination of participant in clinical trial. Used as the secondary diagnosis for all claims with research-related items and services. Note: If used as the primary diagnosis, then the claim will be rejected. Used for inpatient and hospital outpatient claims and physician billing. 120
121 Q0/Q1 Modifiers placed after CPT code on: Hospital outpatient claims Physician billing claims Not used in inpatient hospital claims Not used for services on claims which are not related to the research study Line item by line item use 121
122 Q0/Q1 Q0 Investigational clinical service provided in a clinical research study that is in an approved clinical research study. Q1 - Routine clinical service provided in a clinical research study that is in an approved clinical research study. 122
123 Q0 Investigational clinical services are defined as those items and services that are being investigated as an objective within the study. Investigational clinical services may include items or services that are approved, unapproved, or otherwise covered (or not covered) under Medicare. Examples: Study drugs that are billable Category B devices Investigational devices with Medicare approval Laboratory tests which are identified in the objectives as instrumental to the hypothesis 123
124 Q1 Routine clinical services are defined as those items and services that are covered for Medicare beneficiaries outside of the clinical research study; are used for the direct patient management within the study; and, do not meet the definition of investigational clinical services. Routine clinical services may include items or services required solely for the provision of the investigational clinical services (e.g., administration of a chemotherapeutic agent); clinically appropriate monitoring, whether or not required by the investigational clinical service (e.g., blood tests to measure tumor markers); and items or services required for the prevention, diagnosis, or treatment of research related adverse events (e.g., blood levels of various parameters to measure kidney function). (emphasis added) 124
125 Condition Code 30 Used on the claim form whenever a V70.7 is used One-for-one use 125
126 A note on the medical record Section 69.3 of Ch. 32 also contains the following: The billing provider must include in the beneficiary's medical record the following information: trial name, sponsor, and sponsor-assigned protocol number. This information does not need to be submitted with the claim but must be provided if requested for medical review. (emphasis added) 126
127 Add-on that applies to all: Identifying treatment of complications Note that in some studies, the sponsor will pay for unscheduled events and treatment of complications. A system needs to be devised to identify these Suggestion: Flag studies in database which pay for treatment of complications or unscheduled events Batch ED census and bump against subject database for the flagged studies Hold charges for any matched Obtain information from PI/study coordinator 127
128 Useful for Effective CRB Claims Management Database of research studies Database of research subjects CAs/tool
129 Questions? 4147 N Ravenswood Ave Ste. 200 Chicago, IL www. aegis- compliance. com 129
September 20, 2012. Kelly Willenberg, MBA, BSN, CHC, CHRC. Kelly Willenberg, LLC
September 20, 2012 Kelly Willenberg, MBA, BSN, CHC, CHRC 1 1 Understand the importance of research billing compliance and how that impacts the hospital and your practice Understand how billing can advance
More informationCoverage Analysis: The Cornerstone of Clinical Research Billing Presented by: Mary L. Veazie, CPA, MBA, CHC, CHRC Executive Director, Clinical
Coverage Analysis: The Cornerstone of Clinical Research Billing Presented by: Mary L. Veazie, CPA, MBA, CHC, CHRC Executive Director, Clinical Research Finance The University of Texas MD Anderson Cancer
More informationMedicare Billing. Lisa R. Pitler, JD, MS, RN Assistant Vice Chancellor Research, Director of Clinical Trials Office University of Illinois at Chicago
Medicare Billing Lisa R. Pitler, JD, MS, RN Assistant Vice Chancellor Research, Director of Clinical Trials Office University of Illinois at Chicago May 14, 2015 Presentation Objectives Understand and
More informationMedical Billing Human Research Studies Seminar Notes
Audits If a department learns that an external audit is going to be initiated, the Billing Compliance Department and Research Administration should be notified when the scope of the audit involves billing
More informationPart D Drugs & Medicare Coverage Rules
Part D Drugs & Medicare Coverage Rules Ryan Meade, JD Meade & Roach, LLP RMeade@MeadeRoach.com 312.498.7004 Kristin H. West, JD Assoc. V.P. & Director, Office of Research Compliance Emory University kwest02@emory.edu
More informationClinical Trials Budgeting and Billing
Clinical Trials Budgeting and Billing Presented by: Ellen N. Jamieson, MS, MBA Director, Grants Administration Alexandria Hui, BA Manager, Clinical Trial Financial Analyst Rules and Regulations Medicare
More informationCoverage Analysis. Purpose
Coverage Analysis Purpose The purpose of this policy is to provide a method for researchers to perform a Coverage Analysis (CA) for clinical research conducted at Mission Hospital, Inc., Memorial and St.
More informationClinical Research Management Webinar Series: How to Process Medicare Advantage Claims for Research Billing
Clinical Research Management Webinar Series: How to Process Medicare Advantage Claims for Research Billing Wednesday, September 19, 2012 12:00 p.m. - 1:00 p.m. CT About Our Speakers Allecia A. Harley Director,
More informationSTANDARD OPERATING PROCEDURE FORMAL COVERAGE ANALYSIS
PURPOSE Establish a consistent comprehensive coverage analysis process that is well defined and performed on every clinical trial. UCSF REQUIREMENT Effective 6/1/2013, a formal coverage analysis must be
More informationQualified Clinical Trials
Compliance Clinical trials are carefully designed research studies that test promising new cancer treatments, and help researchers determine the overall efficacy and therapeutic value of a new drug or
More informationPlease log onto the audio portion of this webinar: Session 6
Please log onto the audio portion of this webinar: Session 6: Dial in: 866 740 1260 Access Code: 9870028 1 University of California Clinical Research Billing Education Series September October 2010 Session
More informationReview current regulatory climate Budget development Coverage analysis Charge reconciliation / 3 rd party billing Lessons learned
Meeting the Challenge of Compliant Clinical Research Billing Kathy Hammerhofer, BSN, RN Kelly Nottingham, MPH, CHES Objectives Review current regulatory climate Budget development Coverage analysis Charge
More informationIs it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
More information9/4/2013. Medicare NCD for Qualifying Trials. Coverage Based on Medical Necessity. Medicare National Coverage Determinations (NCD) for Clinical Trials
DUHS Compliance Presentation Date: September 11, 2013 Medicare National Coverage Determinations (NCD) for Clinical Trials Presented by Jan Collins, Compliance Auditor for Clinical Trials Page 1 Medicare
More informationContents: Centers for Medicare/Medicaid (CMS) Clinical Trials Policy (CTP) Training. CMS CTP Background, Definitions and Requirements
Contents: CMS CTP Background, Definitions and Requirements Process Going Forward UW Medicine Process Reminders April 2009, Slide 1 Background: In 2000, Medicare issued a National Coverage Decision (NCD)
More informationEXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND I. INTRODUCTION: Scope. To the extent of any conflict between the Agreement and this State
More informationDEFINITIONS: POLICY: Office for the Protection of Research Subjects Institutional Review Board. Page 1 of 5 OVCR Document #0933
Office for the Protection of Research Subjects Institutional Review Board Sponsor Payment for Costs Related to Subject Injury in Industry- Sponsored Clinical Trials Guidance Version: 1.2 Date: 3/27/2015
More informationCMS Issues Proposal to Revise Clinical Trial Policy National Coverage Determination
Covington & Burling llp Brussels London New York San Francisco Washington Health Care E-Alert May 3, 2007 CMS Issues Proposal to Revise Clinical Trial Policy National Coverage Determination Recently, the
More informationRoutine Costs in a Clinical Trial (NCD 310.1)
Policy Number 310.1 Approved By UnitedHealthcare Medicare Committee Current Approval Date 12/16/2015 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare Medicare
More informationComments on Information Collection Request for Healthcare Common Procedure Coding System
September 17, 2007 Reference No.: FASC07061 Bonnie L. Harkless Division of Regulations Development Office of Strategic Operations and Regulatory Affairs Centers for Medicare and Medicaid Services Room
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationRegulatory Compliance Policy No. COMP-RCC 4.20 Title:
I. SCOPE: Regulatory Compliance Policy No. COMP-RCC 4.20 Page: 1 of 11 This policy applies to (1) Tenet Healthcare Corporation and its wholly-owned subsidiaries and affiliates (each, an Affiliate ); (2)
More informationRegulatory Compliance Policy No. COMP-RCC 4.07 Title:
I. SCOPE: Regulatory Compliance Policy No. COMP-RCC 4.07 Page: 1 of 7 This policy applies to (1) any Hospital in which Tenet Healthcare Corporation or an affiliate owns a direct or indirect equity interest
More informationROLE OF THE RESEARCH COORDINATOR Study Start-up Best Practices
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Study Start-up
More information2. For all clinical trials, the coverage analysis will also be audited to ensure compliance with the Medicare National Coverage Determination.
COMPLIANCE PROGRAM POLICY: Clinical Research Billing Audit Policy Effective Date: August 1, 2014 Last Updated: Page 1 of 8 I. POLICY All UC Irvine Health departments engaged in clinical research may be
More informationCOM Compliance Policy No. 3
COM Compliance Policy No. 3 THE UNIVERSITY OF ILLINOIS AT CHICAGO NO.: 3 UIC College of Medicine DATE: 8/5/10 Chicago, Illinois PAGE: 1of 7 UNIVERSITY OF ILLINOIS COLLEGE OF MEDICINE CODING AND DOCUMENTATION
More informationIntroduction to Clinical Research
Introduction to Clinical Research NCURA Region I Spring Meeting May 5, 2015 Agenda Introductions Brief History of Clinical Research Clinical Research in Context Clinical Research Compliance Clinical Research
More informationGuidance for Industry
Guidance for Industry Charging for Investigational Drugs Under an IND Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationGuidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationLUNG CANCER CLINICAL TRIALS
UNDERSTANDING LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 TABLE OF CONTENTS INTRODUCTION TO CLINICAL TRIALS What Is a Clinical Trial?...4 Types of Clinical
More informationSplit Billing Overview
Split Billing Overview June 2, 2008 Doug McGregor Partner, Healthcare Services Feeley & Driscoll, P.C. (617) 742-7788 DougM@fdcpa.com Definitions Split Billing reimbursement A structure under which two
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationBilling an NP's Service Under a Physician's Provider Number
660 N Central Expressway, Ste 240 Plano, TX 75074 469-246-4500 (Local) 800-880-7900 (Toll-free) FAX: 972-233-1215 info@odellsearch.com Selection from: Billing For Nurse Practitioner Services -- Update
More informationThe Changing Face of Medical Necessity under ICD-10
The Changing Face of Medical Necessity under ICD-0 Sponsored by 95 N. Fine Ave #04 Fresno CA 93720-565 Phone: (559) 25-5038 Fax: (559) 25-5836 www.californiahia.org Program Handouts Monday, June 8, 205
More informationUW MEDICINE IDE/HDE DEVICE COVERAGE AND BILLING MAY, 2013
UW MEDICINE IDE/HDE DEVICE COVERAGE AND BILLING MAY, 2013 DEFINITIONS Investigational Device Exemption (IDE)- An approved IDE means that an IRB (and FDA for significant risk devices) has approved the sponsor
More informationUNIFORM HEALTH CARRIER EXTERNAL REVIEW MODEL ACT
Model Regulation Service April 2010 UNIFORM HEALTH CARRIER EXTERNAL REVIEW MODEL ACT Table of Contents Section 1. Title Section 2. Purpose and Intent Section 3. Definitions Section 4. Applicability and
More informationPayment Policy. Evaluation and Management
Purpose Payment Policy Evaluation and Management The purpose of this payment policy is to define how Health New England (HNE) reimburses for Evaluation and Management Services. Applicable Plans Definitions
More informationGuidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues
Office for Human Research Protections (OHRP) Department of Health and Human Services (HHS) Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues This guidance represents
More informationClinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
More informationDecember 13, 2011 Maureen Coyne
December 13, 2011 Maureen Coyne No industry relationships No financial conflicts of interests Recent experience weighted toward industrysponsored clinical trials Information based on my experiences IRB
More informationLABORATORY COMPLIANCE AND MEDICAL NECESSITY
LABORATORY COMPLIANCE AND MEDICAL NECESSITY Jump to: Medical Necessity Local/National Coverage Determinations Advance Beneficiary Notice (ABN) ABN Form in English ABN Form in Spanish Annual Physician Notification
More informationInpatient or Outpatient Only: Why Observation Has Lost Its Status
Inpatient or Outpatient Only: Why Observation Has Lost Its Status W h i t e p a p e r Proper patient status classification affects the clinical and financial success of hospitals. Unfortunately, assigning
More informationHow to Develop a Clinical Study Site Budget
How to Develop a Clinical Study Site Budget Mary Fautsch Dale Klous White Paper 6/23/2011 Abstract Summary In today s dynamic environment, there is a need like never before for clinical data. In addition
More informationGLOSSARY OF MEDICAL AND INSURANCE TERMS
GLOSSARY OF MEDICAL AND INSURANCE TERMS At Westfield Family Physicians we are aware that there are lots of words and phrases we used every day that may not be familiar to you, our patients. We are providing
More informationInvestigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
More informationICD-10 Frequently Asked Questions
ICD-10 Frequently Asked Questions ICD-10 General Overview... 3 What is ICD-10?... 3 Why are we adopting ICD-10?... 3 What are the benefits of the ICD code expansion?... 3 What does ICD-10 compliance mean?...
More informationInformation Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office
More informationOffice of Research Administration: Clinical Research Contracting
Office of Research Administration: Clinical Research Contracting Presented to: Research Administration Professionals Group Presented by: Patricia Travis and Mont Brownlee October 22, 2013 1 Training Agenda
More informationFormulary Management
Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective
More informationMandatory Reporting of National Clinical Trial (NCT) Identifier Numbers on Medicare Claims Qs & As
Mandatory Reporting of National Clinical Trial (NCT) Identifier Numbers on Medicare Claims Qs & As Background Medicare may pay for items and services in clinical research studies under three policies:
More informationBringing New Medical Technology to Market: Understanding CMS Coverage and Payment Determinations*
Bringing New Medical Technology to Market: Understanding CMS Coverage and Payment Determinations* John J. Smith, M.D., J.D. 1 Jennifer A. Henderson, J.D., M.P.H. 2 1 John J. Smith, M.D., J.D., is an Associate
More informationFederally Qualified Health Centers (FQHC) Billing 1163_0212
Federally Qualified Health Centers (FQHC) Billing 1163_0212 Today s Presenter Charles Wiley- Provider Outreach and Education Representative 2 Disclaimer has produced this material as an informational reference
More informationRole of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
More informationMEDICAL ASSOCIATES HEALTH PLANS HEALTH CARE SERVI CES POLICY AND PROCEDURE MANUAL POLICY NUMBER: PP 60
POLICY TITLE: CRITERIA UTILIZED IN DETERMINATION OF MEDICAL NECESSITY. POLICY STATEMENT: MAHP utilizes evidence based medicine in its decision making process. This policy is to establish and maintain medical
More informationIncident To Services
Policy Number INT04242013RP Approved By Incident To Services UnitedHealthcare Medicare Committee Current Approval Date 11/18/2015 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable
More informationANNUAL NOTICE TO PHYSICIANS
NOVEMBER 2014 ANNUAL NOTICE TO PHYSICIANS Dear Physician Colleague: Genoptix Medical Laboratory is committed to complying with all applicable laws and regulations governing the health care industry. We
More informationThe Third National Medicare RAC Summit
The Third National Medicare RAC Summit Major Hospital Vulnerabilities II: Medical Necessity and Clinical Documentation Issues in Medicaid and RAC Audits Edmund L. Lafer, MD Temple University Health System
More informationSociety of Corporate Compliance and Ethics
Society of Corporate Compliance and Ethics 8 th Annual Conference for Effective Compliance Systems in Higher Education We Are Special!! The Special Need for Contract Management for the Health Sciences
More informationPROPOSED US MEDICARE RULING FOR USE OF DRUG CLAIMS INFORMATION FOR OUTCOMES RESEARCH, PROGRAM ANALYSIS & REPORTING AND PUBLIC FUNCTIONS
PROPOSED US MEDICARE RULING FOR USE OF DRUG CLAIMS INFORMATION FOR OUTCOMES RESEARCH, PROGRAM ANALYSIS & REPORTING AND PUBLIC FUNCTIONS The information listed below is Sections B of the proposed ruling
More informationFlorida Clinical Trials Agreement
Florida Clinical Trials Agreement Agreement to Reduce Cancer Morbidity and Mortality in Florida The undersigned parties to this Florida Clinical Trials Agreement (Agreement) acknowledge that Florida ranks
More informationAnthem Workers Compensation
Anthem Workers Compensation ICD-10 Frequently Asked Questions What is ICD-10? International Classification of Diseases, 10th Revision (ICD-10) is a diagnostic and procedure coding system endorsed by the
More informationeskbook Emerging Life Sciences Companies second edition Chapter 18 Medicare Reimbursement for Drugs and Devices
eskbook Emerging Life Sciences Companies second edition Chapter 18 Medicare Reimbursement for Drugs and Devices Chapter 18 MEDICARE REIMBURSEMENT FOR DRUGS AND DEVICES Coverage Coding There is no reimbursement
More informationDevelopment and Implementation of the Reimbursement Strategy. Patty Curoe Telgener, RN, MBA VP of Reimbursement Services Emerson Consultants, Inc.
Development and Implementation of the Reimbursement Strategy Patty Curoe Telgener, RN, MBA VP of Reimbursement Services Emerson Consultants, Inc. 1 Emerson Consultants, Inc. is a full service Consulting
More informationComments and Responses Regarding Draft Local Coverage Determination: Outpatient Physical and Occupational Therapy Services
Comments and Responses Regarding Draft Local Coverage Determination: Outpatient Physical and Occupational Therapy Services As an important part of Medicare Local Coverage Determination (LCD) development,
More informationCENTERS FOR MEDICARE & MEDICAID SERVICES. Medicare & Clinical Research Studies
CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare & Clinical Research Studies You may have the choice to join a clinical research study to diagnose or treat an illness. If you join a covered clinical research
More informationMedicare. Medicare Overview. Medicare Part D Prescription Plans. Medicare
58 requires enrollment as soon as a retiree, spouse or dependent of a retiree is eligible for. Parts A & B MUST be elected. Overview There are three parts to : Hospital Insurance (also called Part A. Your
More informationSTATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services
STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of: Petitioner, v Blue Care Network of Michigan, Respondent. File
More informationA guide for the patient
Understanding series LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS The Basics What is a Clinical Trial?...3 Types of Clinical Trials... 3 Phases
More informationMEDICARE PAYMENTS FOR DIAGNOSTIC RADIOLOGY SERVICES IN EMERGENCY DEPARTMENTS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL MEDICARE PAYMENTS FOR DIAGNOSTIC RADIOLOGY SERVICES IN EMERGENCY DEPARTMENTS Daniel R. Levinson Inspector General April 2011 OEI-07-09-00450
More informationGuidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions
Guidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions U.S. Department of Health and Human Services Food and Drug Administration Center for
More information800 17th Street, NW Suite 1100, Washington, DC 20006
800 17th Street, NW Suite 1100, Washington, DC 20006 September 3, 2015 Mr. Andrew Slavitt Acting Administrator, Centers for Medicare & Medicaid Services Department of Health and Human Services Hubert H.
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationGone are the days when healthy
Five Common Coding Mistakes That Are Costing You Fix these problems to increase your bottom line. GREG CLARKE Emily Hill, PA-C Gone are the days when healthy third-party reimbursements meant practices
More informationANESTHESIA - Medicare
ANESTHESIA - Medicare Policy Number: UM14P0008A2 Effective Date: August 19, 2014 Last Reviewed: January 1, 2016 PAYMENT POLICY HISTORY Version DATE ACTION / DESCRIPTION Version 2 January 1, 2016 Under
More informationMedicare Part B vs. Part D
Medicare Part B vs. Part D 60889-R8-V1 (c) 2012 Amgen Inc. All rights reserved 2 This information is provided for your background education and is not intended to serve as guidance for specific coding,
More informationTHE CITY OF VIRGINIA BEACH AND THE SCHOOL BOARD OF THE CITY OF VIRGINIA BEACH
THE CITY OF VIRGINIA BEACH AND THE SCHOOL BOARD OF THE CITY OF VIRGINIA BEACH OPTIMA November 7, 2013 TABLE OF CONTENTS Executive Summary... 1 Process Overview... 4 Areas of Testing... 5 Site Visit Selection...
More informationNEGOTIATING CLINICAL TRIAL BUDGETS. Debbie Williams R.N., C.C.R.C., C.R.A., A.B.N.
NEGOTIATING CLINICAL TRIAL BUDGETS Debbie Williams R.N., C.C.R.C., C.R.A., A.B.N. A.B.N. Amateur Budget Negotiator OVERVIEW Budget Types Analyzing the Protocol Negotiating the Contract Discussion / Tips
More informationGuidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects
Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationClarifying Questions and Answers Related to the July 6, 2015 CMS/AMA Joint Announcement and Guidance Regarding ICD-10 Flexibilities
Clarifying Questions and Answers Related to the July 6, 2015 CMS/AMA Joint Announcement and Guidance Regarding ICD-10 Flexibilities Question 1: When will the ICD-10 Ombudsman be in place? (revised 09/22/2015)
More informationFor Retirees of City of Memphis. Features that Add Value. Freedom of Choice. Quality Service Is Part of Quality Care
For Retirees of City of Memphis Features that Add Value The Cigna Medicare Surround indemnity medical plan helps pay some of the health care costs that your Medicare Part A or Part B do not cover such
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENTAL APPEALS BOARD DECISION OF MEDICARE APPEALS COUNCIL
DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENTAL APPEALS BOARD DECISION OF MEDICARE APPEALS COUNCIL In the case of Claim for Advanced Diabetes Supplementary Medical Treatment Centers Insurance Benefits
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationCardiac Rehabilitation and Intensive Cardiac Rehabilitation JA6850
Cardiac Rehabilitation and Intensive Cardiac Rehabilitation JA6850 Related CR Release Date: March 21, 2010 Revised Date Job Aid Revised: November 17, 2010 Effective Date: January 1, 2010 Implementation
More informationUse of Electronic Health Record Data in Clinical Investigations
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationExpanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
More informationNEW YORK STATE EXTERNAL APPEAL
NEW YORK STATE EXTERNAL APPEAL You have the right to appeal to the Department of Financial Services (DFS) when your insurer or HMO denies health care services as not medically necessary, experimental/investigational
More informationTexas Mandated Benefit Cost and Utilization Summary Report. October 2005 - September 2006 Reporting Period. Texas Department of Insurance
Texas Mandated Benefit Cost and Utilization Summary Report October 2005 - September 2006 Reporting Period Texas Department of Insurance Table of Contents Executive Summary.. 1 Survey Overview..... 5 Legislation...........
More informationGEORGIA MEDICAID TELEMEDICINE HANDBOOK
GEORGIA MEDICAID TELEMEDICINE HANDBOOK CONNECTING GEORGIA OVERVIEW The Department of Community Health s (DCH) Telemedicine and Telehealth policies are slated to improve and increase access and efficiency
More informationPolicy YSM2102 Medical Billing Compliance for Clinical Services Provided to Subjects Who Participate in Clinical Trials and Other Research Studies
Policy YSM2102 Medical Billing Compliance for Clinical Services Provided to Subjects Who Participate in Clinical Trials and Other Research Studies Responsible Office(s) Responsible Official(s) Yale Faculty
More informationLEGISLATURE OF THE STATE OF IDAHO Sixtieth Legislature First Regular Session 2009 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO.
LEGISLATURE OF THE STATE OF IDAHO Sixtieth Legislature First Regular Session 0 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. BY BUSINESS COMMITTEE 0 AN ACT RELATING TO HEALTH INSURANCE; AMENDING TITLE,
More informationMedical Necessity LMHS Medical Staff Education Presented by:
Medical Necessity LMHS Medical Staff Education Presented by: Lee Memorial Health System Corporate Compliance Department 1 June 2014 Medical Necessity Is it Reasonable and Necessary? Medicare Definition:
More information2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
More informationAdverse Events in Clinical Trials: Definitions and Documentation
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions
More informationCLINICAL RESEARCH ROLES CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES
CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES 1. Clinical Study Team Principal Investigator Co Principal Investigator (Co PI) Research Coordinator Study Monitor Data manage Sponsor Post Doctoral Scholar
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationAHS s Headache Coding Corner A user-friendly guide to CPT and ICD coding
AHS s Headache Coding Corner A user-friendly guide to CPT and ICD coding Stuart Black, MD Part 3 - Medical Decision Making (MDM) coding in Headache As stated in the CPT codebook, the classification of
More informationInitial Preventive Physical Examination
Initial Preventive Physical Examination Overview The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 expanded Medicare's coverage of preventive services. Central to the Centers
More informationMEDICARE PHYSICAL THERAPY. Self-Referring Providers Generally Referred More Beneficiaries but Fewer Services per Beneficiary
United States Government Accountability Office Report to Congressional Requesters April 2014 MEDICARE PHYSICAL THERAPY Self-Referring Providers Generally Referred More Beneficiaries but Fewer Services
More informationEnsure that coders and physicians understand the intricacies of medical necessity
Ensure that coders and physicians understand the intricacies of medical necessity JANUARY 14, 2009 JustCoding.com - January 14, 2009 by Glenn Krauss, BBA, RHIA, CCS, CCS-P, CPUR, PCS, FCS, C-CDIS Medical
More informationSUMMARY OF MARYLAND STATE EMPLOYEES & RETIREES BEHAVIORAL HEALTH PLAN
SUMMARY OF MARYLAND STATE EMPLOYEES & RETIREES BEHAVIORAL HEALTH PLAN January 1, 2014-December 31, 2014 Call APS Healthcare Toll-Free: 1-877-239-1458 Customer Service for Hearing Impaired TTY: 1-877-334-0489
More information